BlackRock Health Sciences Trust Business Summary

BlackRock Health Sciences Trust (BME) is a closed-end management investment company that generates revenue through asset-based management fees and the performance of its diversified healthcare portfolio. The Trust’s business model focuses on providing total return through a combination of current income, capital gains, and long-term appreciation by investing at least 80% of its assets in equity securities of companies within the health sciences and related industries, including pharmaceuticals, biotechnology, and medical devices. To enhance yield and mitigate volatility, BME employs a strategic covered call option-writing strategy on a portion of its underlying holdings. Its primary business segments are categorized by sub-sector exposure, with significant weightings in health care equipment, providers, and services. Direct competitors include the abrdn Healthcare Opportunities Fund (THQ), abrdn World Healthcare Fund (THW), and the Gabelli Healthcare & WellnessRx Trust (GRX); BME distinguishes itself in this landscape through its long-standing track record of monthly distributions and a focus on high-quality, blue-chip healthcare equities. The Trust is overseen by a sophisticated leadership team led by John M. Perlowski, who serves as President and Chief Executive Officer, and Trent Walker as Chief Financial Officer. The investment strategy is executed by the BlackRock Fundamental Equities Health Sciences team, headed by Managing Director and Lead Portfolio Manager Dr. Erin Xie, who has managed the fund since its 2005 inception and previously held senior roles at State Street Research & Management and Sanford C. Bernstein. The portfolio management team also includes Managing Directors Kyle McClements and Christopher M. Accettella, alongside Director Xiang Liu, PhD. Governance is provided by a Board of Trustees chaired by Dr. R. Glenn Hubbard, a former Chairman of the U.S. Council of Economic Advisers, and Vice Chairman Dr. W. Carl Kester, a distinguished professor at Harvard Business School, ensuring high-level fiduciary oversight and strategic alignment with institutional standards.